Dupixent® ( dupilumab ) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria ( CSU )
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo ...
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
5 %
|
|
META
|
Neutral
|
1 %
|
|
SNY
|
Neutral
|
12 %
|
